Many studies have highlighted the critical role of c-Kit in normal melanocyte development but its role in melanoma development remains unclear. Although c-Kit expression is often lost during melanoma progression, a subset of melanoma has been found to overexpress c-Kit and mutations activating c-Kit have recently been identified in some acral and mucosal melanoma. To address the role of these c-Kit mutants in the transformation of melanocytes, we characterized the physiological responses of melanocytes expressing the most frequent c-Kit mutants found in melanoma (K642E and L576P) and a novel mutant we identified in an acral melanoma. We analysed signaling pathways activated downstream of c-Kit and showed that all three mutants led to a strong activation of the phosphatidyl-inositol-3 kinase (PI3K) pathway but only weak activation of the Ras/Raf/Mek/Erk pathway, which was not sufficient to promote uncontrolled melanocyte proliferation and transformation. However, in hypoxic conditions or coexpressed with a constitutively active form of hypoxia-inducible factor 1a (HIF-1a), c-Kit mutants activate the Ras/Raf/Mek/Erk pathway, stimulate proliferation and transform melanocytes. Proliferation of melanocytes transformed by these mutants was specifically inhibited by imatinib. These results show for the first time that melanocytes require a specific epigenetic environment to be transformed by c-Kit mutants and highlight a distinct molecular mechanism of melanocyte transformation.
Introduction
The proto-oncogene c-Kit has an essential role in melanocyte physiology, influencing proliferation, migration and survival of these pigment-producing cells. Insights into the role of c-Kit have been greatly facilitated by the large series of naturally occurring mutations in its murine and human genes. Inactivating mutations that impair c-Kit kinase activity lead to various developmental disorders that result in amelanotic congenital patches of white skin associated with human piebaldism and mouse dominant white spotting (Geissler et al., 1988; Giebel and Spritz, 1991) . c-Kit (also known as CD117) is a type III receptor tyrosine kinase characterized by the presence of five immunoglobulin-like domains in its extracellular portion. Stem cell factor (SCF), its ligand, binds to the second and third immunoglobulin domains, whereas the fourth domain has a role in receptor dimerization (Roskoski, 2005) . Binding of SCF to c-Kit induces receptor dimerization and autophosphorylation of specific tyrosine residues in its intracellular domain. These phosphorylation events create docking sites for specific Src homology 2 (SH2) domain-containing proteins, which in turn control various intracellular signaling pathways. Numerous signaling molecules have been identified as binding partners for specific phospho-tyrosine (pTyr) residues on activated c-Kit, including the p85 subunit of the phosphatidyl-inositol-3 kinase (PI3K), phospholipase C, the Grb2 and Grb7 adapter proteins, Src family kinases and the protein tyrosine phosphatases SHP-1 and SHP-2 (Lennartsson et al., 2005) . The recruitment of binding partners is cell specific and will determine the effect of SCF on each cell type. At present, it is not completely clear which pathways contribute to the biological responses of melanocytes to SCF. Although many studies have highlighted the critical role of c-Kit in normal melanocyte development, its role in melanoma development remains controversial. Until recently, data suggested that c-Kit might act as a tumor-suppressor gene in melanoma. Indeed, c-Kit is expressed in melanocytes, benign melanocytic nevi and in situ malignant melanoma, but tends to be reduced or lost with tumor progression to invasive and metastatic melanoma (Natali et al., 1992) . Furthermore, c-Kit expression is lost in most melanoma cell lines (Lassam and Bickford, 1992) . One hypothesis was that c-Kit signaling was important for melanocyte differentiation, and therefore, loss of its expression was a required step in the course of tumor progression. However, the role of c-Kit in melanomagenesis is likely to be more complex as a subset of melanoma has been found to maintain c-Kit overexpression, even in metastatic lesions, and mutations activating c-Kit have recently been identified in some melanoma Beadling et al., 2008) . Acral and mucosal melanoma are subsets of melanoma presenting mutations in the c-Kit gene. All these mutations are present in exons 11, 13, 17 and 18 of the gene, Lys 642 to Glu (K642E) and Leu 576 to Pro (L576P) being the most frequent. The biological significance of c-Kit mutations in melanoma remains unclear as there are currently no c-Kit-mutated melanoma cell lines available to analyse the oncogenic properties of c-Kit and the effect of c-Kit inhibitors on melanoma proliferation. These cell lines are essential to perform preclinical studies in order to determine whether patients with melanoma bearing c-Kit mutations could benefit from treatment with one of the c-Kit inhibitors available in the clinics. It was recently shown that an Asp 814 to Tyr (D814Y) c-Kit mutant, found in gastrointestinal stromal tumors, did not stimulate melanocyte proliferation nor induce their transformation (Alexeev and Yoon, 2006) , suggesting that c-Kit mutants are not oncogenic in melanocytes. However, D814Y is localized in the kinase domain of c-Kit, whereas most of the mutations found in melanoma are localized in the juxtamembrane domain of c-Kit. Different mutations may activate different signaling pathways and those will ultimately determine the effect of c-Kit mutations in each cell type. We decided to investigate the oncogenic properties and signaling pathways activated by juxtamembrane domain mutants in melanocytes. To address this question, we characterized the physiological responses of melanocytes expressing the c-Kit mutants K642E and L576P, as well as a novel mutant we identified in an acral melanoma. We analysed signaling pathways activated downstream of c-Kit and showed that all three mutants led to a strong activation of the PI3K pathway, but that this was not sufficient to promote uncontrolled melanocyte proliferation and their transformation. However, these mutants cooperated with hypoxia and hypoxia-inducible factor 1a (HIF-1a) to activate the Ras/Raf/Mek/Erk pathway, stimulate proliferation and transform melanocytes. Cells transformed with a mutant c-Kit became very sensitive to the c-Kit inhibitor, imatinib.
Results

c-Kit mutants are not oncogenic in melanocytes
Genetic aberrations affecting c-Kit occur in melanoma of the mucosa, acral skin and skin with sun-induced damage. The most frequent point mutations being K642E ( K642E c-Kit) and L576P ( L576P c-Kit). We recently identified a novel c-Kit mutation in a primary acral melanoma of the foot, consisting of a homozygote deletion of the three bases coding for L576 ( c-Kit induced the transformation of melanocytes, we expressed these mutants, as well as the wild-type receptor c-Kit in immortal mouse melanocytes, and selected for transformants in a PMA-free medium; under these conditions, only transformed cells are able to grow. As a control, we used oncogenic forms of N-Ras ( (Figure 2a ). This phosphorylation of the receptor resulted in strong phosphorylation of the protein Akt on Ser473. Akt phosphorylation induced by SCF was superior to the one induced by G12V N-Ras in melan-a cells even at the lowest dose of SCF (10 ng/ml) ( Figure 2b ). As Y721 in the kinase-insert domain of the human c-Kit receptor serves as a binding site for PI3K (Serve et al., 1995) , we analysed the phosphorylation of this site using a phospho-specific antibody and showed that phosphorylation of Y721 paralleled Akt activation (Figure 2a) . Moreover, p85, the regulatory subunit of PI3K, was recruited to the c-Kit receptor in the presence of its ligand in the same dose-dependent manner (Figure 2a) . Interestingly, c-Kit activation by SCF induced only a weak activation of Erk when compared with PMA or G12V N-Ras even at the highest dose of SCF (100 ng/ml) ( Figure 2b ). These data show that SCF preferentially activated the PI3K/Akt pathway over the Ras/Raf/Mek/Erk pathway downstream of c-Kit in melanocytes.
In melanocytes expressing the c-Kit and K642E c-Kit explains our observed lack of tumorigenicity of these mutants in melanocytes ( Figure 1 ). To extend our results to endogenous c-Kit in human cells, we used the 501mel human melanoma cell line, which retains the expression of endogenous c-Kit. SCF treatment of these cells induced a dose-dependent phosphorylation of c-Kit Y721 associated with a strong activation of Akt (Figure 4 ). This shows that, in human melanocyte-derived cells, SCF is as strong an activator of the PI3K pathway as in murine melanocytes. In 501mel cells, the Erk pathway is constitutively activated by a B-Raf mutation (da Rocha Dias et al., 2005) and insensitive to SCF. To confirm these results in vivo, we examined c-Kit expression and Akt phosphorylation in situ using immunohistochemistry In the tumor, but not in the surrounding normal tissue, we showed a diffuse and strong c-Kit immunoreactivity associated with a strong signal from phospho-Akt ( Figure 5 ). This suggests an activation of the PI3K pathway in this tumor because of the presence of mutant c-Kit, as seen in our cell culture experiments.
c-Kit mutants cooperate with HIF-1a to transform melanocytes Although constitutive Akt is not able to transform melanocytes in normoxic conditions (Bedogni et al., 2005) and N Dumaz, unpublished data), it has recently been shown that it can transform melanocytes in a hypoxic environment and that the synergy between Akt and hypoxia is HIF-1a mediated. To investigate the role of hypoxia in melanocyte transformation by c-Kit mutants, we grew melanocytes expressing WT c-Kit or D576 c-Kit in hypoxic conditions and measured the effect on signaling pathways and proliferation. We showed that the hypoxic environment induced HIF-1a expression, stimulated the PI3K and the Ras/Raf/Mek/Erk pathways in cells expressing c-Kit mutant (Figure 6a ). Proliferation of these cells was stimulated by hypoxia and inhibited by the c-Kit inhibitor imatinib, showing that hypoxia induced proliferation in a c-Kit-dependent manner (Figure 6b ). To study further the role of HIF-1a in melanocyte transformation by c-Kit mutants, we made use of a constitutive form of HIF-1a (401D603), which lacks the oxygen-dependant degradation domain and is therefore stable in normoxic conditions (Huang et al., 1999) . c-Kit and K642E c-Kit were transfected into melan-a cells stably expressing this constitutive form of HIF-1a, and transformed cells were selected in PMA-free medium. Concomitant presence of mutant c-Kit and stable HIF-1a promoted melanocyte transformation as indicated by the growth of colonies in PMA-free medium (Table 1) . As a control, we used G12V N-Ras, which was able to transform HIF-1a-expressing melan-a cells. To test the degree of transformation of the clones expressing mutant c-Kit or N-Ras, N-Ras and stable HIF-1a formed colonies in soft agar, whereas cells expressing HIF-1a alone failed to grow in these conditions (Figure 7 ). These data showed that stable HIF-1a was not oncogenic in melanocytes but that it could act as a promoting factor for the oncogenic c-Kit mutants. These mutants were weaker c-Kit were less sensitive to the Mek inhibitor, U0126, than melanocytes transformed by G12V N-Ras. To analyse the role of Erk activation in vivo, we examined Erk phosphorylation in situ using immunohistochemistry in the acral tumor containing the D576 c-Kit mutation. We could not detect significant activation of Erk in the tumoral tissue ( Figure 5) . Surprisingly, inhibition of HIF-1a expression by RNA interference in transformed melanocytes expressing D576 c-Kit or K642E c-Kit had no effect on Erk activation (Supplementary Figure 2) , suggesting that, in transformed melanocytes, c-Kit mutants can activate the Ras/Raf/Mek/Erk pathway independently of HIF-1a.
Discussion c-Kit mutations have recently been identified in certain subsets of melanoma, such as acral, mucosal and skin with sun-induced damage Beadling et al., 2008) , but the biological significance of these mutations remains unclear. We have shown here for the first time that c-Kit mutants use a different molecular mechanism than N-Ras or B-Raf oncogenes to transform melanocytes. Activation of the c-Kit receptor in melanocytes is primarily responsible for stimulation of the PI3K/Akt pathway rather than the Ras/Raf/Mek/ Erk pathway (Figures 2a and b) . This happens through phosphorylation of Y721 and possibly other c-Kit tyrosines, allowing p85 recruitment and the subsequent activation of the PI3K/Akt pathway (Figures 2a and b) . Although Akt is significantly activated at low physiological doses of SCF (10 ng/ml), Erk is only activated at c-KIT mutants are oncogenic in melanocytes G Monsel et al high doses of SCF (100 ng/ml) (Figure 2a ). These data suggest that, in melanocytes, the PI3K/Akt pathway is preferred over the Ras/Raf/Mek/Erk pathway downstream of c-Kit. The same holds true in human melanoma cells in which activation of endogenous wild-type c-Kit in 501mel cells induced a strong activation of the PI3K/Akt pathway with the lowest dose of SCF (Figure 4) . We also showed that mutations in the c-Kit juxtamembrane domain induced ligandindependent activation of the receptor, indicated by tyrosine phosphorylation of its intracellular domain in melanocytes as previously shown in other cellular systems. Interestingly, these mutations induced constitutive activation of Y721 known to be a binding site for p85 (Figure 3a) . This ligand-independent activation of c-Kit stimulated the PI3K/Akt pathway and only very weakly the Ras/Raf/Mek/Erk pathway (Figure 3b) . These results were extended in vivo to show strong Akt activation, but no Erk activation, in an acral melanoma strongly expressing D576 c-Kit ( Figure 5 ). Our in situ data agree with a recent report describing the activation of Akt in 25 out of 28 acral lentiginous melanoma, although the c-Kit status in these tumors was not determined (Muchemwa et al., 2008) . Together, these data highlight the importance of the PI3K/Akt pathway activation in the development of acral and mucosal melanoma. In accordance, as well as having c-Kit mutations, around 15% of these types of melanoma contain N-Ras mutations, known to activate the PI3K/ Akt pathway, whereas B-Raf mutations, which do not activate the PI3K pathway, are very rare in these tumors. Targeting the PI3K pathway may therefore be of therapeutic interest in acral and mucosal melanoma.
Activation of the PI3K pathway by c-Kit mutants is not sufficient to promote uncontrolled melanocyte proliferation and their transformation (Figure 1 ), suggesting that c-Kit mutants are not oncogenic in melanocytes. However, two melanoma bearing c-Kit mutations have recently shown major responses to treatment with imatinib, a c-Kit inhibitor Lutzky et al., 2008) , indicating that c-Kit mutants Melanocytes expressing c-Kit mutants must hence require a tissue-specific epigenetic environment in vivo that permits the tumorigenic potential of c-Kit mutants, which we did not reproduce in the cell culture conditions used in Figure 1 . Interestingly, we showed that in hypoxia, mutant c-Kit could stimulate the Ras/Raf/ Mek/Erk pathway and melanocyte proliferation ( Figure 6 ). Moreover, these c-Kit mutants cooperated with active HIF-1a to transform melanocytes in culture as measured by the anchorage-independent growth of melanocytes expressing mutant c-Kit and HIF-1a (Table 1 and Figure 8 ). Therefore, in order to acquire a proliferation advantage, melanocytes expressing mutated c-Kit require a tissue-specific environment in vivo allowing activation of HIF-1a, such as hypoxia. The presence of a mild hypoxic environment in the skin has already been described (Bedogni et al., 2005) , but it remains to be determined whether hypoxia is elevated in the skin located at the extremities of the hands and feet or in the mucosa where acral and mucosal melanoma develop. This strict dependency of c-Kit mutants on the microenvironment could explain the low frequency of c-Kit mutations in cutaneous melanoma (around 2%) Beadling et al., 2008) . Interestingly, HIF-1a has also been identified as a target for microphthalmia-associated transcription factor (MITF) (Busca et al., 2005) . MITF, a transcription factor master regulator of melanocyte differentiation and melanoma proliferation, has been found amplified in around 20% of melanoma (Garraway et al., 2005) . It will be interesting to compare MITF expression and c-Kit mutations in acral and mucosal melanoma. Although we showed that HIF-1a is required for the activation of Erk by SCF in WT c-Kit-expressing cells (Figure 8a ), in transformed clones HIF-1a become dispensable for stimulation of the Ras/Raf/Mek/Erk pathway (Supplementary Figure 2 ). We can speculate that HIF-1a is required in the initials steps of melanocyte transformation by mutant c-Kit and that, during transformation, cells acquire further genetic alterations that render HIF1a dispensable. This is in agreement with the fact that acral and mucosal melanoma can metastasize to nonhypoxic environment in the body and therefore have to become independent of HIF-1a.
Erk activation is essential for the proliferation of melanocyte transformation by c-Kit mutants: its inhibition by U0126 blocking cellular proliferation of (Figure 8b ), suggesting that tumors harboring oncogenic c-Kit are less dependent on the Ras/Raf/Mek/Erk pathway than melanoma containing oncogenic N-Ras. This is confirmed by the weak Erk activation seen in situ in the acral tumor containing the D576 c-Kit mutation ( Figure 5 ). This is in agreement with previous study showing that cells driven by mutant receptor tyrosine kinase depend less on Erk signaling for proliferation than those with mutant Ras or Raf (Solit et al., 2006) . There is an apparent discrepancy between the high level of Erk activation in c-Kit mutant. This contradiction could be resolved by considering the implications of feedback downregulation of the pathway as recently suggested by Pratilas et al. (2009) . They showed that Erk signaling is downregulated by a negative feedback in tumoral cells driven by a mutant receptor tyrosine kinase. Such physiological feedback inhibition in the tumor could explain the low level of Erk activation we observed in situ. As Erk activation is necessary for melanocytes transformation in culture, it is likely that we selected for clones strongly activating Erk in PMA-free medium in which the Ras/Raf/Mek/Erk pathway became insensitive to feedback inhibition (Pratilas et al., 2009 ). Our data underline the fact that the three oncogenes found in melanoma, c-Kit, N-Ras and B-Raf, use different molecular mechanisms to transform melanocytes. We have already shown that Ras mutations are not equivalent to B-Raf mutations in melanoma cell lines as they do not activate the Ras/Raf/Mek/Erk pathway in the same way. B-Raf mutations constitutively activate Mek/ Erk, whereas Ras mutation induces a switch in signaling from B-Raf to C-Raf to activate Mek/Erk (Dumaz et al., 2006) . Our current results on c-Kit mutants show that they do not activate Erk in the absence of HIF-1a but instead use the PI3K/Akt pathway for melanocyte transformation, pointing out the diversity in the mechanism of melanocyte transformation. This is the first description of melanocytes transformed with mutant c-Kit allowing us to study the response of melanoma harboring c-Kit mutants to the c-Kit inhibitor imatinib. By inhibiting c-Kit phosphorylation, imatinib inhibited both the PI3K/Akt pathway and the Ras/Raf/Mek/Erk pathway specifically, whereas both pathways were resistant to the c-Kit inhibitor in G12V N-Ras-transformed melanocytes. We showed that the proliferation and anchorage-independent growth of melanocytes transformed with c-Kit mutants were totally inhibited by 1 mM imatinib (Figures 7b and 8b) , whereas melanocytes transformed with oncogenic N-Ras were resistant to the same treatment. These data show that c-Kit mutants are bona fide oncogenes in melanocytes and hence good therapeutic targets. They confirm the recently published data obtained in the M6 melanoma cell line, which harbors the V599A c-Kit mutant (Jiang et al., 2008) , and also agree with the recent in vivo responses to imatinib treatment of two melanoma bearing c-Kit mutations Lutzky et al., 2008) . Several clinical trials are under way for the treatment of melanoma harboring c-Kit mutants with various c-Kit inhibitors, imatinib, sunitinib and dasatinib. Our results point to some biological markers (HIF-1a, pY721 c-Kit, pAkt) that would be interesting to follow in treated patients.
Materials and methods
Melanoma sample
A frozen fragment of an acral lentiginous melanoma of the feet was obtained from the Pathology Department (Hoˆpital Henri Mondor, Cre´teil, France) following informed consent and institutional approval by an ethics committee. Genomic DNA (DNeasy Blood & Tissue Kit, Qiagen, Courtaboeuf, France) and total RNA (RNeasy Mini Kit, Qiagen) were extracted following the manufacturer's instructions to analyse the c-Kit mutation status as previously described .
Vector construction
Alternative mRNA splicing results in the production of two isoforms of c-Kit in human cells, characterized by the presence or absence of four amino acids, GNNK, in the juxtamembrane region of the extracellular domain (Voytyuk et al., 2003) . Analysis revealed the absence of the 12 bases coding for GNNK in the acral melanoma harboring the D576 c-Kit mutation (Supplementary Figure 1a) . Therefore all the c-Kit constructs used in this study were devoid of the 12 bases coding for these four amino acids. Wild-type c-Kit, kindly provided by Dr Ro¨nnstrand (Lund University, Malmo, Sweden), was subcloned in the pMCEF vector (Dumaz et al., 2006) . Mutations were introduced by site-directed mutagenesis and confirmed by sequence analysis. HIF-1a (401D603), kindly provided by Dr Bunn (Brigham and Women's Hospital, Boston, MA, USA), was subcloned in the pEF vector (Invitrogen, Cergy Pontoise, France).
Cell culture
Melan-a cells, a nontransformed mouse line that retains many of the characteristics of normal melanocytes (Bennett et al., 1987) , were maintained in RPMI 1640 (Invitrogen) containing 10% fetal calf serum (FCS; Perbio, Brebie`res, France), antibiotics (penicillin/streptomycin; Invitrogen), 200 nM 12-Otetradecanoylphorbol-13-acetate (PMA; Sigma, Saint-Quentin Fallavier, France) and 300 pM cholera toxin (Sigma) at 37 1C and 5% CO 2 . Cells were transfected using LipofectAMINE in OptiMEM I (Invitrogen) according to the manufacturer's instruction and selected by G418 (50 mg/ml; PAA) in the presence or absence of PMA (200 nM). Clones were stained after 2-3 weeks with 0.5% crystal violet. 501mel human melanoma cell lines (a gift from Pr Marais) were maintained in RPMI 1640 containing 10% FCS. Before SCF (Peprotech, Neuilly-sur-Seine, France) treatment, cells were maintained for 16 h in PMA-free medium (melan-a cells) or serum-free medium (501mel). To measure proliferation in normoxia, DNA synthesis was determined using thymidine as previously described (Dumaz et al., 2006) . To create a hypoxic environment, cells were grown in a hypoxic chamber in 1% oxygen in a 37 1C incubator. Cells were lysed after 4 h of hypoxia for protein analysis or incubated 3 days in hypoxia after which proliferation was measured by an MTT assay. Stealth small interfering RNA (siRNA) probes (Invitrogen) had the following sequence: control (SCR) 5 0 -AAGACCUUUAUCUCUU ACUCCUUGG-3 0 ; HIF-1a 5 0 -CCAUGAGGAAAUGAGAG AAAUGCUU-3 0 . Exponentially growing cells were transfected with 20 pmol of siRNA with lipofectAMINE following the manufacturer's instructions and cells were lysed 3 days later.
Soft agar assay 1 Â 10 4 cells were resuspended in 0.45% low melting point (LMP) agarose in RPMI 1640 containing 10% FCS and overlaid onto 0.9% LMP agarose in RPMI 1640 containing 10% FCS in 6-well plates. Fresh medium (1 ml) containing dimethylsulfoxide or imatinib was added twice a week for 3 weeks after which colonies were counted.
Protein expression
Cells were lysed in 50 mM Tris (pH 7,5), 150 mM NaCl, 0.5% NP40, 5 mM NaF, 2 mM Na 3 VO 4 , 10 mg/ml leupeptin and 10 mg/ml aprotinin for 10 min at 4 1C. Protein concentrations were determined with the Protein Assay Kit (Bio-Rad, Marnes-la-Coquette, France). For immunoprecipitation, samples were incubated with 1 mg of HA (Roche, Neuilly-sur-Seine, France) or c-Kit (clone C-19, Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies for 1 h and immunoprecipitated by protein G Sepharose (GE Healthcare, Aulnay sous Bois, France) for 1 h at 4 1C. The immune complexes were washed three times with lysis buffer. Proteins were separated by SDS-polyacrylamide gel electrophoresis and western blot analysis was carried out following standard protocols using the following antibodies: c-Kit, p85 (Cell Signaling Technology, Danvers, MA, USA), phospho-c-Kit (Y721; Cell Signaling Technology), phospho-tyrosine (clone 4G10; Upsate/Millipore, Molsheim, France), phospho-Erk (MAPK-YT; Sigma), Erk1/2 (Upstate/Millipore), phosphoAkt (Ser473; Cell Signaling Technology), Akt (Cell Signaling Technology) and HIF-1a (Bethyl Laboratories, Montgomery, TX, USA).
In situ analysis In situ expression analysis of c-Kit, phosphorylated Akt and phosphorylated Erk1/2 was carried out using immunohistochemistry in a formalin-fixed, paraffin-embedded tissue sample obtained from an acral melanoma containing the D576 c-Kit mutation. As primary antibodies, we used an anti-CD117 rabbit polyclonal antibody (code A4502, Dako France SAS, Trappes, France), the phospho-Akt (Ser473; Cell Signaling c-KIT mutants are oncogenic in melanocytes G Monsel et al
